What happens when trastuzumab emtansine patent ends in 2023?
According to [1] DrugPatentWatch.com, the patent for trastuzumab emtansine is expected to expire in 2023. This may lead to a shift in the competitive landscape for breast cancer treatments.
With the patent expiry, multiple biosimilars and generic versions of trastuzumab emtansine are likely to enter the market. Companies like Mylan, Teva, and Pfizer have already received FDA approval for their versions of the drug. [2]
How will this impact Roche's sales and market share?
Roche, the company currently holding the patent for trastuzumab emtansine, may see a decline in sales and market share as cheaper alternatives become available on the market. However, Roche has been diversifying its portfolio and pipeline in recent years, which may help mitigate this impact.
Can biosimilars enter the market before patent expiry?
The Biologics Price Competition and Innovation Act (BPCIA) requires biosimilar developers to provide 180 days of notice before launching their product. This means that biosimilars may be able to enter the market before the patent expires, potentially challenging Roche's sales.
How does this affect existing patients and their treatment options?
The patent expiry and subsequent entry of biosimilars are expected to increase access to affordable treatments for patients with HER2-positive breast cancer. Healthcare providers may be able to offer patients multiple treatment options at different price points, depending on their individual needs and insurance coverage.
What side effects are patients asking about?
While the patent expiry is likely to increase competition and potentially decrease prices, patients should be aware of the potential side effects associated with trastuzumab emtansine, including neutropenia, thrombocytopenia, and cardiotoxicity.
Sources:
[1] DrugPatentWatch.com: Trastuzumab Emtansine (T-DM1) Generic and Biosimilar Approvals
[2] FDA: Approval Briefing Document for T-Dxy - biosimilar version of T-DM1